Argenica Therapeutics Management

Management Kriterienprüfungen 2/4

Wir verfügen derzeit nicht über ausreichende Informationen über den CEO.

Wichtige Informationen

Liz Dallimore

Geschäftsführender

AU$424.2k

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts	67.8%
Amtszeit als Geschäftsführer	2.6yrs
Eigentum des Geschäftsführers	1.3%
Durchschnittliche Amtszeit des Managements	keine Daten
Durchschnittliche Amtszeit der Vorstandsmitglieder	1.6yrs

Jüngste Management Updates

Recent updates

Argenica Therapeutics (ASX:AGN) Is In A Good Position To Deliver On Growth Plans

Sep 23

Companies Like Argenica Therapeutics (ASX:AGN) Are In A Position To Invest In Growth

Jan 12

Argenica Therapeutics (ASX:AGN) Is In A Good Position To Deliver On Growth Plans

Aug 12

Here's Why We're Not Too Worried About Argenica Therapeutics' (ASX:AGN) Cash Burn Situation

Apr 29

Here's Why We're Not Too Worried About Argenica Therapeutics' (ASX:AGN) Cash Burn Situation

Dec 30

We're Not Very Worried About Argenica Therapeutics' (ASX:AGN) Cash Burn Rate

Sep 16

Analyse der Geschäftsführervergütung

Wie hat sich die Vergütung von Liz Dallimore im Vergleich zu den Einnahmen von Argenica Therapeutics verändert?
Datum	Gesamtvergütung	Gehalt	Unternehmensgewinne
Jun 30 2024	AU$424k	AU$288k	-AU$5m
Mar 31 2024	n/a	n/a	-AU$5m
Dec 31 2023	n/a	n/a	-AU$5m
Sep 30 2023	n/a	n/a	-AU$5m
Jun 30 2023	AU$675k	AU$250k	-AU$5m
Mar 31 2023	n/a	n/a	-AU$4m
Dec 31 2022	n/a	n/a	-AU$4m
Sep 30 2022	n/a	n/a	-AU$4m
Jun 30 2022	AU$337k	AU$228k	-AU$4m
Mar 31 2022	n/a	n/a	-AU$3m
Dec 31 2021	n/a	n/a	-AU$3m
Sep 30 2021	n/a	n/a	-AU$2m
Jun 30 2021	AU$145k	AU$31k	-AU$1m

Vergütung im Vergleich zum Markt: LizDie Gesamtvergütung ($USD276.54K) liegt im Durchschnitt der Unternehmen ähnlicher Größe auf dem Markt Australian ($USD298.50K).

Entschädigung vs. Einkommen: LizDie Vergütung des Vorstandsvorsitzenden entsprach im vergangenen Jahr der Unternehmensleistung.

Geschäftsführer

Liz Dallimore

2.6yrs

Amtszeit

AU$424,246

Vergütung

Dr. Liz Dallimore (B. Sc. (Hons), MBA, PhD, GAICD) serves as Chief Executive Officer of Argenica Therapeutics Limited ands serves as its Managing Director and Director since April 4, 2022. She is a researc...

Vorstandsmitglieder

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Liz Dallimore	CEO, MD & Director	2.6yrs	AU$424.25k	1.28% A$ 1.2m
Dianne Angus	Independent Non-Executive Chairman	less than a year	AU$102.58k	keine Daten
Geoffrey Donnan	Member of Clinical Advisory Committee	no data	keine Daten	keine Daten
Terence Budge	Independent Non-Executive Director	3.8yrs	AU$44.40k	0.63% A$ 584.1k
Robert Black	Independent Non-Executive Director	less than a year	keine Daten	0.020% A$ 18.1k
Paul Bailey	Member of Clinical Advisory Committee	no data	keine Daten	keine Daten
Tim Phillips	Member of Clinical Advisory Committee	no data	keine Daten	keine Daten
David Blacker	Chairman of Clinical Advisory Committee	no data	keine Daten	keine Daten
Jeffery Saver	Member of Clinical Advisory Committee	2.3yrs	keine Daten	keine Daten
Mark Etherton	Independent Non-Executive Director	less than a year	keine Daten	keine Daten

1.6yrs

Durchschnittliche Betriebszugehörigkeit

Erfahrener Vorstand: AGNDie Vorstandsmitglieder gelten nicht als erfahren ( 1.6 Jahre durchschnittliche Amtszeit), was auf einen neuen Vorstand hindeutet.

Argenica Therapeutics Management

Management Kriterienprüfungen 2/4

Wichtige Informationen

Jüngste Management Updates

Ms. Liddy Mccall Intends Not Stand for Re-Election as Non-Executive Director of Argenica Therapeutics Limited

Less than half of directors are independent

Argenica Therapeutics Limited, Annual General Meeting, Nov 12, 2024

Argenica Therapeutics Limited Announces Changes to its Board, Effective 1 December 2023

Argenica Therapeutics Limited, Annual General Meeting, Nov 30, 2023

Less than half of directors are independent

Recent updates

Ms. Liddy Mccall Intends Not Stand for Re-Election as Non-Executive Director of Argenica Therapeutics Limited

Argenica Therapeutics (ASX:AGN) Is In A Good Position To Deliver On Growth Plans

Less than half of directors are independent

Argenica Therapeutics Limited, Annual General Meeting, Nov 12, 2024

Argenica Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 12 million.

New major risk - Revenue and earnings growth

New minor risk - Share price stability

Companies Like Argenica Therapeutics (ASX:AGN) Are In A Position To Invest In Growth

Argenica Therapeutics Limited Announces Changes to its Board, Effective 1 December 2023

Argenica Therapeutics Limited, Annual General Meeting, Nov 30, 2023

Argenica Therapeutics (ASX:AGN) Is In A Strong Position To Grow Its Business

Argenica Therapeutics (ASX:AGN) Is In A Strong Position To Grow Its Business

Argenica Therapeutics Limited Announces Preclinical Data Shows ARG-007 Inhibits A Cause of Alzheimers

Argenica Therapeutics Limited Announces Successful Completion of Phase 1 Clinical Trial Dosing

Argenica Therapeutics Limited Announces Successful Completion of Phase 1 Clinical Trial Dosing

Argenica Therapeutics Limited Approves Commencement of Fourth and Final Cohort Dosing

We're Not Very Worried About Argenica Therapeutics' (ASX:AGN) Cash Burn Rate

Argenica Therapeutics Limited Announces That the First Subjects in the Third Cohort of Its Phase 1 Clinical Trial of ARG-007 Have Been Dosed

Argenica Therapeutics Limited Announces the Approval by the Phase 1 Safety Review Committee (SRC) to Progress to the Third Escalated Dose Cohort

Less than half of directors are independent

Argenica Therapeutics Limited Announces Sentinel Subjects Dosed in Second Cohort of Phase 1 Trial

Argenica Therapeutics Limited Announces the Approval by the Phase 1 Safety Review Committee to Progress to the Second Escalated Dose Cohort

Argenica Therapeutics Limited Announces Healthy Participants in the First Cohort of Its Phase 1 Clinical Trial of ARG-007 Have Been Successfully Dosed, Indicating Good Safety and Tolerability of ARG-007 in These Participants

Argenica Therapeutics Limited Announces First Healthy Adult Subject Dosed in Phase 1 Trial of ARG007

Argenica Therapeutics Limited Announces Further Positive Preclinical Results for ARG-007 in Hypoxic-Ischaemic Encephalopathy

Argenica Therapeutics Limited, Annual General Meeting, Nov 24, 2022

Argenica Therapeutics Limited Announces Phase 1 Clinical Trial Summary

Argenica Therapeutics Limited Receives Ethics Approval to Commence Phase 1 Trial

Argenica Therapeutics (ASX:AGN) Is In A Good Position To Deliver On Growth Plans

Argenica Therapeutics Limited Submits Application to Seek Approval to Commence Phase 1 Healthy Participant Study of ARG-007

Argenica Therapeutics Limited Appoints Dr. Jeffery Saver to Clinical Advisory Committee

Argenica Therapeutics Limited Announces Completion of the Final Pharmacokinetic (PK) Study of ARG-007 Required for the Phase 1 Clinical Trial

Here's Why We're Not Too Worried About Argenica Therapeutics' (ASX:AGN) Cash Burn Situation

Argenica Therapeutics Limited Announces Results of In-Life Rodent and Non-Human Primate Toxicology Studies Which Have Established the Maximum Tolerated Dose (MTD) of ARG-007

Less than half of directors are independent

Less than half of directors are independent

Argenica Therapeutics Limited Announces Management Changes

Argenica Therapeutics Limited Announces Positive Preclincal Data on Efficacy of ARG-007

Argenica Therapeutics Limited Announces Successful Completion of Final GLP Genotoxicity Studies

Argenica Therapeutics Announces Completion of Preliminary Pre-Clinical Tox Studies

Here's Why We're Not Too Worried About Argenica Therapeutics' (ASX:AGN) Cash Burn Situation

We're Not Very Worried About Argenica Therapeutics' (ASX:AGN) Cash Burn Rate

Argenica Therapeutics Limited Provides Additional Information of Study Shows ARG-007 Does Not Degrade

Argenica Therapeutics Limited Provides Positive Preliminary for ARG-007

Argenica Therapeutics Limited Completes Pilot Pre-Clinical Pharmacokinetics Study

Argenica Therapeutics Limited has completed an IPO in the amount of AUD 7 million.

Analyse der Geschäftsführervergütung

Geschäftsführer

Amtszeit

Vergütung

Vorstandsmitglieder

Durchschnittliche Betriebszugehörigkeit